Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine the excretion balance and systemic exposure of radioactivity after oral
administration of [14C]-SAR442168.
To determine the pharmacokinetics of SAR442168 and its contribution to the overall exposure
of radioactivity.
To collect samples in order to determine the metabolic pathways of SAR442168 and identify the
chemical structures and main excretion route of the main metabolites (samples will be
analyzed according to metabolic analysis plan and results will be documented in a separate
report).
Secondary Objective:
To assess the clinical and biological tolerability of an oral solution of SAR442168.